Robbie Williams Warns of Serious Vision Issues He Believes Linked to Weight-Loss Jab Mounjaro

Pop star Robbie Williams has publicly claimed that his worsening eyesight is tied to the weight-loss injection Mounjaro, raising fresh concerns around the medication’s potential side-effects and prompting both caution and controversy.

A Star’s Vision Trouble

The 51-year-old former member of Take That says that after beginning the jab he noticed his vision becoming increasingly blurry. Onstage, in everyday life and even during an American football game, Williams says individual players began to appear as mere “shapes” on the field. He told The Sun:

“I was quite an early adopter of the jabs … what I’m also noticing is that my eyesight’s not very good. It’s been blurry for a while now, and it’s only getting worse. I don’t believe it’s age; I believe it’s the jabs.” (Source: The Sun)

Despite seeing an optician, changing his prescription and buying numerous new glasses, he says the problem persists. He added:

“I’m that sick I’d probably stay on it until the sight in one eye has completely gone.”

What Robbie Says He Gains — and Loses

While Williams worries about his declining vision, he also credits the injections with a major uplift in his mental-health and self-care, stating that he’s felt a lack of “mental anguish” since taking Mounjaro. This dual narrative — of improvement and risk — has added complexity to public discussion around the drug.

Robbie has said he’s had to get all new glasses (Credit: Splash News)

The Larger Picture: Vision Risks and Mounjaro

Mounjaro (generic name tirzepatide) is prescribed for type-2 diabetes and increasingly used off-label for weight loss. While its benefits are well documented, emerging research is raising red flags about possible rare vision issues. According to an overview:

• The drug’s official prescribing guide lists vision-changes as a possible side effect. (§)

• Reviews show instances of blurred vision and rare conditions like non-arteritic anterior ischemic optic neuropathy (NAION) in patients using GLP-1 agonists—including tirzepatide. (Sources: JAMA Ophthalmology, UKMeds)

• One legal website notes patients with Mounjaro have reported eye-twitching, floaters, dry eyes and vision loss.
  
  Robbie says he won’t stop the jab till his sight has gone ‘completely’ in one eye (Credit: YouTube)

  In one article summarising the evidence:

  “GLP-1 medicines such as … Mounjaro … can cause side effects including blurred vision … one study suggests an increased risk of NAION.”

  What the Manufacturer Says

  The maker of Mounjaro, Eli Lilly and Company, stated that patient safety is its “top priority” and that it is in “ongoing discussion with regulators regarding potential safety topics, and will continue to review data, including any regarding ophthalmic issues.” (Source: LADbible)

  Why This Matters

  Robbie Williams’ public disclosure brings several issues into sharper relief:

  • The growing popularity of GLP-1-based weight-loss injections and the need for full awareness of potential side-effects.

  • The possibility that temporary vision changes may mask longer-term risk, especially among non-diabetic users.

  • The tension between perceived wellness gains (weight-loss, improved mood) and possible latent harms.
    For a high-profile user like Williams to voice concern may prompt others to reassess their use of such medications or consult their doctors more closely.

  What to Watch

  • Will large-scale studies confirm a causal link between tirzepatide-class drugs and vision damage?

  • Will regulatory bodies update guidance or issuance of warnings about ocular risks?

  • Will users who experience vision changes while on such medications speak out or seek legal recourse?

  • How will the balance of benefit vs risk play out, especially in the non-diabetic “wellness” market?